Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)

Axsome Therapeutics dosed the first patient in its Phase 3 FOCUS-2 trial of solriamfetol for children with ADHD. The study plans to randomize ~468 patients (1:1:1) to two solriamfetol doses or placebo for 6 weeks, with the primary endpoint measuring change in ADHD-RS-5 total score by week 6. This expands the solriamfetol clinical program alongside the already-initiated FOCUS-3 adolescent trial, supporting a longer runway for additional label expansion.

Analysis

This is more lifecycle-management than a near-term earnings event. The market is likely to treat the first pediatric dose as a low-signal de-risking step, not as a revenue inflection, so upside in AXSM should be limited unless the company can later show clean tolerability plus a meaningful effect size versus placebo. The real valuation question is whether solriamfetol can become a multi-indication CNS asset or remains a niche sleep product with optionality.

Competitive dynamics matter more than the press release tone suggests. The closest public read-through is SUPN, because any credible non-stimulant ADHD data in children can pressure the premium narrative around alternative ADHD therapies; however, the pediatric market is unforgiving on side effects, so even a statistically positive result may not convert into durable prescribing if appetite, sleep, or CV signals emerge. Stimulant generics still set the efficacy bar, which means this program needs to beat not just placebo but entrenched habit.

The catalyst path is months, not days: enrollment pace, futility language, and AE disclosures are what matter until data. Falsifiers are straightforward: protocol slippage, safety imbalance, or a weaker-than-expected signal in adolescents before the child study matures. Contrarian view: the stock may be underpricing the optionality of a second pediatric indication, but it may also be overestimating how much a crowded ADHD landscape can monetize a late-stage readout without a clearly differentiated tolerability profile.

Key Decisions for Investors

• No immediate trade on the first-patient-dosed announcement; treat AXSM as a watch item until enrollment/safety cadence is visible over the next 1-2 quarters.
• If AXSM sells off on the news, consider a small starter long for a 6-12 month horizon; thesis is that the market is underweight the lifecycle optionality, but size should stay modest because commercial impact is still unproven.
• Set an alert for any ADHD-related safety language in FOCUS-2/3; a CV, appetite, or insomnia signal would likely kill the pediatric expansion story and should be a clear exit trigger.
• Relative-value watch: AXSM vs SUPN. If later data strengthen the pediatric ADHD narrative, a long AXSM / short SUPN pair could express the view that Axsome has more upside optionality, but it is premature before efficacy readouts.
• Do not use options aggressively here without a readout date; the expected move is likely too small for premium capture unless the stock rerates on broader pipeline optionality.